MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$756,415
Free Cash flow
-$1,101,448
Unit: Dollar
Positive Cash Flow Breakdown
Accounts receivable
Accrued expenses, operating leas...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Net loss
Fair value change in warrant lia...
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,006,331
-2,382,022
-1,437,890
-1,619,221
Amortization and depreciation
47,002
60,029
65,523
64,324
Amortization of deferred issuance costs
-
-
-
0
Stock-based compensation
352,777
342,135
359,255
358,560
Debt and equity facility costs reclassified to financing activities
-
-
-
141,416
Valuation adjustments for excess or obsolete inventory
1,000
-
-
2,500
Non-cash lease expense
30,024
29,476
28,944
28,426
Fair value change in warrant liability
-405,702
8,271
-222,740
314,751
Accounts receivable
-798,418
-764,484
1,397,062
1,264,805
Inventory
191,839
433,268
-560,658
331,604
Prepaid expenses
35,224
129,189
13,155
-91,991
Accounts payable
-33,326
380,240
-439,992
526,943
Accrued expenses, operating leases and other liabilities
361,412
31,133
-619,376
302,463
Net cash used in operating activities
-1,081,789
-1,328,711
-3,115,835
-1,525,672
Purchase of property and equipment
19,659
38,516
40,754
10,607
Net cash used in investing activities
-19,659
-38,516
-40,754
-10,607
Proceeds from issuance of common stock attributed to non-private placement equity offerings
-
-
-
9,614,037
Issuance costs attributed to common stock and warrants issued in private placement
-
-
-
185,903
Proceeds from issuance of common stock attributed to equity financings
358,986
-8,943,637
-
-
Issuance costs related to non-private placement equity offerings
-
-
-
1,045,971
Issuance costs related to equity financings
-10,777
-
-
-
Deferred issuance costs in connection with debt facility
-
-
-
0
Deferred issuance costs in connection with at-the-market offering program
0
0
22,920
-
Exercise of warrants
0
-1
174,375
69,750
Share repurchases for the payment of employee taxes
3,176
60,777
3,632
2,771
Net cash provided by financing activities
345,033
609,622
147,823
66,978
Net (decrease) increase in cash and cash equivalents
-756,415
-757,605
-3,008,766
-1,469,301
Cash and cash equivalents at beginning of period
3,561,616
3,561,616
6,570,382
1,460,042
Cash and cash equivalents at end of period
2,047,596
2,804,011
3,561,616
6,570,382
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock...
$358,986
(-96.27%↓ Y/Y)
Net cash provided by
financing activities
$345,033
(-95.67%↓ Y/Y)
Canceled cashflow
$13,953
Net (decrease)
increase in cash and cash...
-$756,415
(-111.50%↓ Y/Y)
Canceled cashflow
$345,033
Accounts receivable
-$798,418
(-352.01%↓ Y/Y)
Accrued expenses,
operating leases and other...
$361,412
(201.26%↑ Y/Y)
Stock-based compensation
$352,777
(-61.06%↓ Y/Y)
Amortization and
depreciation
$47,002
(-76.18%↓ Y/Y)
Non-cash lease expense
$30,024
(-63.91%↓ Y/Y)
Valuation adjustments for
excess or obsolete...
$1,000
(-86.67%↓ Y/Y)
Issuance costs related to
equity financings
-$10,777
Share repurchases for
the payment of...
$3,176
(-97.39%↓ Y/Y)
Net cash used in
operating activities
-$1,081,789
(17.52%↑ Y/Y)
Canceled cashflow
$1,590,633
Net cash used in
investing activities
-$19,659
(72.36%↑ Y/Y)
Net loss
-$2,006,331
(-1.02%↓ Y/Y)
Fair value change in
warrant liability
-$405,702
(63.10%↑ Y/Y)
Inventory
$191,839
(126.28%↑ Y/Y)
Prepaid expenses
$35,224
(108.40%↑ Y/Y)
Accounts payable
-$33,326
(88.39%↑ Y/Y)
Purchase of property and
equipment
$19,659
(-72.36%↓ Y/Y)
Buy us a coffee
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)